FOXO1 and familial dilated cardiomyopathy: In 2021, several studies proved inhibition of FoxO1 may be an approach to alleviate cardiac fibrosis, diastolic dysfunction, and left ventricular dysfunction and remodeling in the mouse model of DCM (93–95).